TTLL8

Across TCGA pan-cancer cohorts, TTLL8 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TTLL8 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TTLL8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TTLL8 expression acts as an unfavorable survival marker.

STAD, LUSC, and LIHC are the cancer types where TTLL8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	18	view →
LIHC	OS	Median	II,III,IV	0.010	0.716	<.001	12	view →
COAD	DFS	Median	IV	0.035	0.501	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.307	0.834	.002	6	view →
BLCA	DFS	Median	III,IV	0.132	0.572	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TTLL8–STAD (OS)

Open the STAD breakdown →